Nasiri, A., El Fakih, R. orcid.org/0000-0003-4498-3865, Chabannon, C. orcid.org/0000-0002-3755-4889 et al. (33 more authors) (2026) Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article. Bone Marrow Transplantation. ISSN: 0268-3369
Abstract
Chimeric antigen receptor T-cell therapy transformed the treatment of hematologic malignancies and is rapidly expanding into solid tumors and autoimmune diseases. However, its full clinical potential remains constrained by centralized manufacturing, production costs, logistical complexity, prolonged vein-to-vein times, limited global accessibility, and regulatory frameworks that hinder rapid implementation of manufacturing innovations. Decentralized point-of-care manufacturing, pioneered by academic and clinical centers, offers a promising alternative to address these limitations and broaden patient access. This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations. Program experience across North America, Europe, Asia, and other regions demonstrates manufacturing innovations that reduce production times from several weeks to as few as 6–8 days. Early clinical studies report safety and efficacy comparable to commercially manufactured products while substantially lowering costs, with some models targeting production expenses of approximately USD 40,000 per treatment (excluding building and maintaining the production facility). We also examine supportive policy initiatives and regulatory pathways, including hospital exemption models, together with implementation challenges such as manufacturing heterogeneity, quality assurance, and workforce development. Finally, we discuss emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, that may democratize global access.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © 2026 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in Bone Marrow Transplantation is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Biomedical and Clinical Sciences; Immunology; Transplantation; Hematology; Gene Therapy; Immunotherapy; Biotechnology; Cancer; Genetics; Clinical Research; Cellular and gene therapies; Good Health and Well Being |
| Dates: |
|
| Institution: | The University of Sheffield |
| Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
| Date Deposited: | 09 Oct 2026 10:15 |
| Last Modified: | 09 Oct 2026 12:31 |
| Status: | Published online |
| Publisher: | Springer Science and Business Media LLC |
| Refereed: | Yes |
| Identification Number: | 10.1038/s41409-026-03044-3 |
| Related URLs: | |
| Sustainable Development Goals: | |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:246493 |
Download
Filename: Nisiri_et_al_BMT_2026_31781_2_merged_1788770655.pdf
Licence: CC-BY 4.0


CORE (COnnecting REpositories)
CORE (COnnecting REpositories)